Thus, we envisage that an apoE4 blood marker assay based on this development could be easily incorporated into routine dementia test profiles, allowing a fast identification of APOE ε4 carriers in the clinic for patient stratification and identification of those at increased risk of AD and cardiovascular disorders, as well as clinical trial enrichment. This evidence concerns the gene APOE and cardiovascular disorder.